Blog Menu

Pharmaceutical News Wrap Up: November 2014

Here at Simmons Hanly Conroy, our pharmaceutical lawyers understand the importance of staying up to date on the latest pharmaceutical news. Below is a list of some of the most recent headlines concerning U.S. Food and Drug Administration (FDA) recalls, approvals and warning label changes, medical studies and other pharmaceutical news taking place throughout the world.

  • Bleeding risk from blood thinner Pradaxa higher than first reported
    This Harvard editorial piece outlines the numerous studies that have linked Pradaxa to increased risk of a major bleed, which has caused dampened enthusiasm for the drug since its FDA approval in 2010.
  • Safety concerns slow sales of testosterone therapy
    Due to a one-year trial by the National Institutes of Health comparing men on a placebo versus men on testosterone, 2015 should shed some light on whether or not testosterone therapy benefits otherwise healthy men. These results could further affect the sales of testosterone medications.
  • Banned drugs still turning up in weight-loss supplements
    Despite FDA recalls for weight loss supplements containing dangerous substances, a study published recently found that two-thirds of the recalled products still contained banned substances. Manufacturers are continuing to produce and distribute the supplements even after FDA intervention.
Read the rest

New Study Links Risperdal and Gynecomastia in Middle-Aged Men

Gynecomastia is a condition that is known to cause breast development and lactation in males. It is also one of the lesser known Risperdal side effects that is common in pre-pubescent boys. It turns out, though, that gynecomastia affects more than just young men. New research from the Journal of Clinical Psychopharmacology has shown a strong link between middle-aged men taking Risperdal and gynecomastia in men taking Risperdal.

prescriptionThe research showed that adult men taking Risperdal had a 69 percent increased risk of gynecomastia compared to men who did not take the medication. As a leading antipsychotic drug, there are approximately 12 million Risperdal prescriptions dispensed each year in the United States, according to the study. Given Risperdal’s popularity, the results of this study are vital for clinicians that are considering prescribing Risperdal.

Gynecomastia itself does not have dangerous implications. But, it does have a variety of psychological side effects. Gynecomastia side effects include:

  • Decreased mental health
  • Lowered social functioning
  • Lowered self-esteem
  • Decreased general health
  • Lowered standard quality of life

About Risperdal and Gynecomastia

Risperdal is an atypical antipsychotic is approved to treat mental disorders such as schizophrenia, autism with irritability, and bipolar disorder. But, Risperdal is sometimes prescribed for a variety of psychological disorders outside of these intended uses.… Read the rest


8 Serious Actos Side Effects You Should Be Aware Of

Side effects of Actos, a prescription drug used to treat diabetes, have shown to be dangerous. An oral medication that lowers blood sugar, Actos is a very popular drug for treating type 2 diabetes. Although some Actos side effects can be innocuous, such as a sore throat or dry mouth, there are quite a large number of side effects that can be symptoms of serious or life threatening issues.

These 8 Actos side effects are known to indicate serious problems:

  • Nausea or vomiting
  • Swelling in areas such as the arms, legs, fingers, feet or face
  • Yellow skin or eyes
  • Tightness in chest
  • Irregular or strained breathing
  • Dark urine
  • Dilated neck veins
  • Irregular bruising or bleeding

Actos and Cancer

These threatening Actos side effects could be associated with the various risks connected to the medication. Already linked to congestive heart failure (CHF), liver problems, and bone fractures, studies have shown Actos and cancer may also have a connection.

In fact, the U.S. Food and Drug Administration (FDA) has already issued an Actos warning about this and has advised that bladder cancer patients should not use the drug. Those with a history of bladder cancer should also be cautious before taking Actos, the agency has instructed.… Read the rest


Male Pattern Baldness Linked to Increased Prostate Cancer Risk

Male pattern baldness has long been a source of anxiety for men, raising concerns of appearance and aging. Aside from aesthetic effects, though, it can have much more serious implications. An early September study on the relationship between male pattern baldness and prostate cancer indicated that there was a definite connection between the two.

baldingSpecifically, men over 45 with vertex pattern balding are at 39 percent higher risk for aggressive prostate cancer. The connecting factor between hair loss and prostate cancer is male hormones, also know as androgens. The androgens testosterone and dihydrotestosterone (DHT) are associated both with balding and with prostate development and cancer. These are most likely the link between the two conditions.

Interestingly, DHT suppression is a main function in the hair loss drug Propecia.

Using Propecia for Hair Loss: Persistent Sexual Side Effects

Although DHT suppression shows success in fighting hair loss, it also contributes to the sexual side effects of Propecia. Propecia’s active ingredient of finasteride is responsible for blocking this hormone as well as for the side effects.
Propecia side effects include:

  • Erectile Dysfunction
  • Loss of Libido
  • Ejaculatory Disorder
  • Genital Soreness/Pain

Unfortunately, some of these side effects, such as erectile problems and reduced libido, can persist long after ceasing to take Propecia.… Read the rest


Pharmaceutical News Wrap Up: October 2014

The Simmons Hanly Conroy pharmaceutical lawyers are dedicated to providing you with the latest pharmaceutical news. Below is a short list of some of the most recent headlines concerning FDA recalls and warning label changes, medical studies and other pharmaceutical news taking place across the globe .

  • Antidote for anticoagulant Pradaxa to be tested in Hamilton
    Read pharmaceutical news from Simmons Hanly ConroyFive Canadian hospitals are participating in a clinical trial that tests an antidote for Pradaxa, a blood-thinning medication that has been linked to serious bleeding. The drug’s manufacturer, Boehringer Igelheim, hopes the antidote will be able to reverse the serious effects of Pradaxa’s anticlotting abilities.

 … Read the rest

170 queries. 4.523 seconds